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96Introduction: As referrals to gender identity clinics have increased dramatically over the last few years, no studies
focusing on older trans people seeking treatment are available.
Aims: The aimof this studywas to investigate the sociodemographic and clinical characteristics of older trans people
attending a national service and to investigate the inﬂuence of cross-sex hormones (CHT) on psychopathology.
Methods: Individuals over the age of 50 years old referred to a national gender identity clinic during a 30-month
period were invited to complete a battery of questionnaires to measure psychopathology and clinical charac-
teristics. Individuals on cross-sex hormones prior to the assessment were compared with those not on treatment
for different variables measuring psychopathology.
Main Outcome Measures: Sociodemographic and clinical variables and measures of depression and anxiety
(Hospital Anxiety and Depression Scale), self-esteem (Rosenberg Self-Esteem Scale), victimization (Experiences
of Transphobia Scale), social support (Multidimensional Scale of Perceived Social Support), interpersonal
functioning (Inventory of Interpersonal Problems), and nonsuicidal self-injury (Self-Injury Questionnaire).
Results: The sex ratio of trans females aged 50 years and older compared to trans males was 23.7:1. Trans males
were removed for the analysis due to their small number (n ¼ 3). Participants included 71 trans females over the
age of 50, of whom the vast majority were white, employed or retired, and divorced and had children. Trans
females on CHT who came out as trans and transitioned at an earlier age were signiﬁcantly less anxious, reported
higher levels of self-esteem, and presented with fewer socialization problems. When controlling for socialization
problems, differences in levels of anxiety but not self-esteem remained.
Conclusion: The use of cross-sex hormones prior to seeking treatment is widespread among older trans females
and appears to be associated with psychological beneﬁts. Existing barriers to access CHT for older trans people
may need to be re-examined.
J Sex Med 2016;-:1e9. Copyright  2016, International Society for Sexual Medicine. Published by Elsevier Inc.
All rights reserved.
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FLA 5.4.0 DTD  JSXM60_proof  8INTRODUCTION
Trans people of all ages have been found to face a number of
difﬁculties, including interpersonal challenges (such as disclosing
their gender identity)1; discrimination and victimization2; low
self-esteem3; body dissatisfaction4; rejection from family and loved
ones5; and self-harming behavior.6,7 Some of those difﬁculties may
be more prevalent among older trans people as ageism, discrimi-
nation in employment, lack of affordable housing, and lack of
social and family support often beset older trans people.8e10
In contemporary Western societies, it is not unusual for trans
people to present to a gender identity clinic service (GICs) at age
50 or older. Trans older adults have been largely invisible in
existing aging and health research.11 Generally subsumed under
the broad umbrella of lesbian, gay, bisexual, and transgender1
February 2016  8:16 pm  ce
Q2






















































































198(LGBT), there has been little information regarding how trans
people differ from nontrans lesbian, gay, and bisexual people or
how trans older adults differ from younger trans adults and cis-
gender (nontrans) older people.12 The literature that does exist
deals mainly with the lack of adequate and appropriate services
for older gender nonconforming and trans people.13 Barriers to
health care are signiﬁcant in this population due to shame,
stigma, lack of educated caregivers, and lack of insurance.14e16
This may increase the difﬁculties accessing services, forcing
older trans people to self-medicate.
Studies investigating the use of cross-sex hormone treatment
(CHT) prior to attending gender identity clinic services among
trans people of all ages found that they most commonly obtain
hormones via the Internet, which leaves these individuals
without the knowledge to minimize health risks.17e19 Trans
people who self-prescribe cross-sex hormones tend to be pre-
dominantly trans women and older when they present to gender
identity clinic services and generally have poor knowledge of the
side effects and risks associated with CHT.17e19 On the positive
side, there is evidence that trans people of all ages who are taking
CHT experience improved quality of life and less social distress,
anxiety, and depression when compared to a population not on
CHT.20e22 However, most of the studies exploring the beneﬁts
of CHT are rarely controlled for other factors known to be
associated with an increased psychopathology, such as social



















This study had 3 main aims. The ﬁrst was to describe the
sociodemographic and clinical features of trans people over the
age of 50 years referred to a national gender identity clinic service
during a 30-month period. The second aim was to collect and
analyze the use and the source of CHT prior to referral to a
gender identity clinic service and to compare trans people who
were using CHT prior to referral with those who did not. Based
on the literature regarding CHT and trans people, it was
hypothesized that the use of CHT will be more prevalent in trans
females17e19 and associated with less anxiety and depression,
fewer self-harming behaviors and discrimination, and increased
self-esteem, social support, and interpersonal functioning.20e22
As an association has been found between socialization prob-
lems and psychopathology in trans people,8,23 the third aim of
the study was to investigate whether differences in psychopa-











The sample consisted of all individuals over the age of 50 who
were referred for an assessment to a national gender identity
clinic service in the United Kingdom during a 30-month period
between November 2012 and June 2015.FLA 5.4.0 DTD  JSXM60_proofPrior to the clinical assessment, every patient was invited to
complete a battery of questionnaires to aid the assessment and
diagnostic procedure. The assessment at the clinic consists of 2
appointments with independent senior clinicians with experience
in the ﬁeld of transgender health. A third appointment with the 2
clinicians, the trans person, and a signiﬁcant other also is orga-
nized to explore and to increase the social support of the indi-
vidual. Following independent assessments and discussion within
the multidisciplinary team, the person is considered for entry
into the treatment program. Treatment, including cross-sex
hormones and gender-related surgeries, is free at the point of
access in the National Health Service (NHS) in the United
Kingdom for all citizens. Patients usually will start CHT if there
are no physical contraindications. Genital reconstructive sur-
geries are generally available to trans people after being in the
treatment program for a minimum of 12 months. We
acknowledge that not all trans people wish to take cross-sex
hormones or undergo gender-related surgeries; a growing num-
ber of trans people express a wish for partial treatment.24 Once
trans people have undergone their desired treatment, follow-up
care can be organized at the service if they wish.16
The study received ethical approval from the Research and
Development Department from the Nottinghamshire Healthcare
NHS Foundation Trust on behalf of the local ethics committee
in line with Health Research Authority guidance.25
MAIN OUTCOME MEASURES
The Hospital Anxiety and Depression Scale (HADS)26 is a 14-
item self-report screening scale originally developed to indicate
the possible presence of anxiety and depression states in the
setting of a medical nonpsychiatric outpatient clinic. HADS
consists of 2 subscales, HAD-Anxiety (HAD-A) and HAD-
Depression (HAD-D), each with seven items, rated on a 4-
point Likert scale (ranging from [0], as much as I always do;
[1] not quite so much; [2] deﬁnitely not so much; to [3] not at
all), indicating either symptoms of anxiety or depression during
the preceding week. A score of 0 to 7 on either scale is regarding
as being in the normal range (no symptoms), a score of 8 to 10 is
suggestive of the presence of a mood disorder (possible symp-
toms), and a score of 11 or higher indicates the probable presence
of a mood disorder (symptoms) of the respective state. Maximum
subscales scores are 21 for depression and anxiety, respectively.
Items referring to symptoms that may have a physical cause are
not included in the scale. The HADS was found to perform well
in assessing the symptom severity and caseness of anxiety dis-
orders and depression in both somatic, psychiatric, and primary-
care patients, and in the general population,27 and it has been
used previously with trans individuals.20,28
The Rosenberg Self-Esteem Scale (RSE)29 is a self-report mea-
sure of global self-esteem. Items are rated on a 4-point rating
scale ranging from 0 (“Strongly disagree”) to 3 (“Strongly agree”).
Its total score is calculated by summing the item scores with
higher scores indicating higher self-esteem. The RSE has beenJ Sex Med 2016;-:1e9



















































































































340empirically validated and administered previously to trans
individuals.30
Self-cutting and its characteristics were assessed by means of
the Self-Injury Questionnaire (SIQ).31 Participants were asked
whether they had ever deliberately cut themselves (yes/no) and if
they had, how long ago they last did this (in the last week,
month, several months ago, more than a year ago, or never). If
they injured themselves during the last week or month, they were
also asked to indicate which body parts were injured; how many
days/month and times/day the cutting occurred; and how often
and how much pain they felt during the cutting. This ques-
tionnaire has also been used in the trans population.6
The Experiences of Transphobia Scale2 assesses experiences of
discrimination or victimization on the basis of gender identity or
gender presentation. The questionnaire was based on the
Transgender Violence Study and measured people’s lifetime ex-
periences of violence and harassment and experiences of any form
of economic discrimination as a result of being trans (eg, verbal
abuse, physical abuse, ﬁred from a job, problems getting a job,
and problems getting health or medical services due to gender
identity or presentation). All 5 items are to be rated on a 4-point
Likert scale ranging from 0 (“never”) to 3 (“several times”).
The Multidimensional Scale of Perceived Social Support
(MSPSS)32 is a 12-item, self-report scale designed to tap social
support from family, friends, and signiﬁcant others. Items are
rated on a 7-point Likert scale ranging from 1 (“very strongly
agree”) to 7 (“very strongly disagree”). The instrument includes 3
subscales to address these 3 types of support (family, friends,
signiﬁcant others). The mean total and subscale scores range
from 1 to 7, with a higher score indicating greater perceived
social support. This scale has recently been used in trans
populations.8
The Inventory of Interpersonal Problems (IIP-32)33 measures
interpersonal difﬁculties. It consists of 32 items to be rated on a
5-point Likert scale ranging from 0 (“Not at all”) to 4
(“Extremely”). There are 8 subscales of interpersonal problems:
Hard to Be Assertive, Hard to Be Sociable, Hard to Be Supportive,
Hard to Be Involved, Too Dependent, Too Caring, Too Aggressive,
and Too Open. A total mean score provides a global measure of
interpersonal distress. Higher subscale scores indicate greater
interpersonal difﬁculties. The IIP-32 is a shortened version of the
original IIP, yet the psychometric properties are retained; a
conﬁrmatory factor analysis demonstrated high reliability with
alpha coefﬁcients of 0.70 to 0.88.33 The IIP-32 has been used
successfully in both nonclinical34 and clinical samples.23
Data Analysis
All quantitative data analyses were performed by means of
SPSS.35 The Kolmogorov-Smirnov Test was used to assess
whether the variables were normally distributed. Given that only
6 variables were normally distributed (age of ﬁrst referral, HADS-
anxiety, Rosenberg Self-Esteem, MSPSS-Family, IIP-32
Nurturance and Total), non-parametric tests were applied. ForJ Sex Med 2016;-:1e9
FLA 5.4.0 DTD  JSXM60_proof  8the ﬁrst aim, descriptive statistics were applied. A quantitative
analysis was performed for the second and third aim. The overall
population will be divided into 2 groups: individuals on CHT
prior to attending the gender identity clinic service and not on
CHT. Both groups will be compared using the c2 test statistic
(for nominal variables), the Mann-Whitney U test (for [non-]
normal continuous variables, aim 2) and MANCOVAs (for
normal distributed continuous variables, aim 3). The level of
signiﬁcance used was P < .05.RESULTS
Sociodemographic and Clinical Characteristics
During the recruitment period of 30 months, 689 individuals
were referred to the clinic, of whom 77 (11.2%) were aged 50
years and older. Three people did not attend their appointment.
Hence, the total sample consisted of 71 (96.2%) trans females
and 3 (3.8%) trans males. Table 1 describes the sociodemo-
graphic and clinical characteristics of the total sample.
The sex ratio of older trans females compared with trans males
was 23.7:1.
The mean age at the time of the assessment of the participants
was 58.9 years (SD ¼ 6.5). In view of the small number of older
trans males attending the clinical service, consequent analysis was
only performed for the 71 trans females.
Out of the 71 trans females, 33 (46.5%) were not taking CHT
prior to their ﬁrst clinic appointment and 38 (53.5%) were. The
mean age of the trans female group at the time of the assessment
and ﬁrst contact with gender services was 59.32 years (SD ¼
6.67). The mean age of coming out was 47.39 years (SD ¼
13.80) and the mean age of social gender role transition was
56.02 years (SD ¼ 9.65). Two people had not come out as trans
and 21 people had not transitioned prior to their ﬁrst appoint-
ment. Coming out concerns the process of becoming open about
your experienced gender with yourself, other people close to you,
and/or publicly. Transition refers to a period of time when in-
dividuals change from the gender role associated with their sex
assigned at birth to a different gender role. For many people, this
involves learning how to live socially in another gender role; for
others this means ﬁnding a gender role and expression most
comfortable for them. Transition may or may not include
feminization or masculinization of the body through cross-sex
hormones or other medical procedures. The nature and dura-
tion of transition are variable and individualized.14 Social gender
role transition is the social portion of a transition, in which a
trans person makes others aware of their gender identity. Some
parts of social transition can include telling people about one’s
gender identity, whether or not they are aware of assigned gender
at birth and/or trans status; changing name used within social
interactions; asking others to use different pronouns, titles and
other gendered language; and changing gender expression.
Table 2 summaries the differences in rates of individuals
taking up CHT prior to referral. Individuals who presented toFebruary 2016  8:16 pm  ce
Q3
Table 1. Sociodemographic and Clinical Characteristics of the Total







n (%) n (%) n (%)
Ethnic origin
White 70 (98.6) 3 (100) 73 (98.6)
Other 1 (1.4) 0 (0) 1 (1.4)
Employment status
Employed 24 (33.8) 1 (33.3) 25 (33.8)
Retired 14 (19.7) 0 (0) 14 (18.9)
Disabled 7 (9.9) 1 (33.3) 8 (10.8)
Unemployed 6 (8.5) 1 (33.3) 7 (9.5)
Volunteer 1 (1.4) 0 (0) 1 (1.4)
Housewife 1 (1.4) 0 (0) 1 (1.4)
Civil status
Single 11 (15.5) 1 (33.3) 12 (16.2)
Married 18 (25.4) 1 (33.3) 19 (25.7)
Civil partner 1 (1.4) 1 (33.3) 2 (2.7)
Divorced 34 (47.9) 0 (0) 34 (45.9)
Widowed 5 (7) 0 (0) 5 (6.8)
In a relation 1 (1.4) 0 (0) 1 (1.4)
Children
No 26 (36.6) 1 (33.3) 27 (36.5)
Yes 45 (63.4) 2 (66.7) 47 (63.5)
Medical history
No 6 (8.5) 1 (33.3) 7 (9.5)
Yes 65 (91.5) 2 (66.7) 67 (90.5)
Psychiatric history
No 32 (45.1) 1 (33.3) 33 (44.6)
Yes 39 (54.9) 2 (66.7) 41 (55.4)
Self-harm
No 68 (95.8) 3 (100) 71 (95.9)
Yes 3 (4.2) 0 (0) 3 (4.1)





































































































441the service on CHT were statistically signiﬁcantly younger at the
time of the assessment. This group also came out and transi-
tioned signiﬁcantly earlier than those trans females not on
treatment (Table 2).
The vast majority of the trans females in the present study
were white, employed or retired; divorced, single or widowed,Table 2. Means (with standard deviations) of the Age, Age at Assessm
Years With and Without Cross-Sex Hormone Treatment (CHT)
Not on CHT On CH
M (SD) M
Age at assessment (n ¼ 71) 60.82 (7.28) 58.03
Age of ﬁrst referral (n ¼ 71) 60.45 (7.34) 56.79
Age of coming out (n ¼ 69) 51.55 (14.04) 43.58
Age of transition (n ¼ 49) 59.35 (10.65) 53.72
*P < .05.
†P < .01.
FLA 5.4.0 DTD  JSXM60_proofand had children, irrespective of the use of CHT prior to their
ﬁrst appointment at the gender clinic service. Additionally, the
majority of trans females report a medical history, with just over
half reporting previous mental health problems, with no signif-
icant differences between trans females who use and do not use
CHT. The levels of self-harm or nonsuicidal self-injury (NSSI)
were small, with 16.9% of the trans females reporting a lifetime
NSSI. The main sociodemographic and clinical variables of the
trans female sample with and without cross-sex hormones
treatment are displayed in Table 3.
Of the 38 trans females on CHT, 21 (55%) had obtained
these via the Internet. The CHT used was estrogen, either in
tablet form or as patches. Eleven out of 21 (52%) trans females
also used at least 1 additional drug that blocked testosterone,
including cyproterone acetate, spironolactone, and ﬁnasteride.
Thirteen people (34%) had obtained CHT via a private physi-
cian; and 4 people (11%) received their hormone treatment from
physicians working in the NHS (3 via their primary care
physician and 1 via a local endocrinologist).Cross-sex Hormone Treatment vs No Treatment
When analyzing the 2 groups of trans females, the study found
signiﬁcant differences between trans females with and without
CHT on the HADS scale scores. Trans females on CHT were
signiﬁcantly less anxious (HADS-A) compared to trans females
not on CHT. Interestingly, no signiﬁcant difference in the level
of HADS-D between the 2 groups was found. Additionally, trans
females on CHT report a signiﬁcantly higher level of self-esteem
compared to trans females not on CHT.
The study found no signiﬁcant overall differences between
trans females with and without CHT on the different MSPSS
scale scores.
Regarding interpersonal problems, trans females on CHT were
found to present with signiﬁcantly less problems with socialization
and in general interpersonal functioning than trans females who
do not use CHT. Finally, with respect to transphobic experiences,
no signiﬁcant differences were found between trans females with
and without cross-sex hormone use (Table 4).
A multivariant analysis (MANCOVA) was performed to
determine whether there were any independent effects (Table 5).ent, Referral, Coming Out, and Transition of Trans Females Over 50
T Total
Mann-Whitney U(SD) M (SD)
(5.87) 59.32 (6.67) 492
(6.59) 58.49 (7.14) 455.5*
(12.61) 47.39 (13.80) 373.5†
(8.32) 56.02 (9.65) 189.5*
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4Table 3. Sociodemographic and Clinical Characteristics of Trans
Females Over 50 Years, With and Without Cross-Sex Hormone
Treatment (CHT) (n ¼ 71)
Not on CHT On CHT Total
c2n (%) n (%) n (%)
Ethnic origin
White 33 (100) 37 (97.4) 70 (98.6) 0.88
Other 0 (0) 1 (2.6) 1 (1.4)
Employment status
Employed 8 (33.3) 16 (55.2) 24 (45.3) 9.37
Retired 9 (37.5) 5 (17.2) 14 (26.4)
Disabled 5 (20.8) 2 (6.9) 7 (13.2)
Unemployed 1 (4.2) 5 (17.2) 6 (11.3)
Volunteer 0 (0.0) 1 (3.4) 1 (1.9)
Housewife 1 (4.2) 0 (0) 1 (1.9)
Civil status
Single 7 (21.9) 4 (10.5) 11 (15.7) 8.80
Married 12 (37.5) 6 (15.8) 18 (25.7)
Civil partner 0 (0) 1 (2.6) 1 (1.4)
Divorced 11 (34.4) 23 (60.5) 34 (48.6)
Widowed 2 (6.3) 3 (7.9) 5 (7.1)
In a relation 0 (0) 1 (2.6) 1 (1.4)
Children
No 12 (36.4) 14 (36.8) 26 (36.6) 0.002
Yes 21 (63.6) 24 (63.2) 45 (63.4)
Medical history
No 2 (6.1) 4 (10.5) 6 (8.5) 0.46
Yes 31 (93.9) 34 (89.5) 65 (91.5)
Psychiatric history
No 15 (45.5) 17 (44.7) 32 (45.1) 0.004
Yes 18 (54.5) 21 (55.3) 39 (54.9)
Self-harm
No 27 (81.8) 32 (84.2) 59 (83.1) 0.07


















































































































567As patients were found to differ with respect to IPP-32 social-
ization based on whether or not they had taken CHT, we
controlled for both variables while comparing patients with and
without CHT on the HADS scales and the Rosenberg Self-
Esteem scale. Overall, we did not ﬁnd signiﬁcant differences
between trans females with and without CHT on the HADS
scale scores while controlling for socialization problems (Wilks’
l ¼ 0.91, F[2,61] ¼ 2.97, ns). On the univariate level, the
difference in the HADS-A between the 2 groups remained and
trans females on CHT were found to be signiﬁcantly less anxious
(HADS-A) compared to trans females not on CHT. Addition-
ally, anxiety/depression was signiﬁcantly positive related to
socialization problems (P < .05).
Trans females with and without CHT did not differ on self-
esteem while controlling for socialization problems. Addition-
ally, higher self-esteem was negatively related to problems with
socialization (P < .01).J Sex Med 2016;-:1e9
FLA 5.4.0 DTD  JSXM60_proof  8DISCUSSION
There has not been any systematic information investigating
sociodemographic and clinical characteristics of older trans peo-
ple. There is no systematic collection of such data in this group
other than case reports,36,37 case series,38,39 and population
samples obtained via the Internet40 or postal questionnaires.12,41
Similarly, there has been no research investigating the role of
CHT in older trans people. This is the ﬁrst study to exclusively
focus on trans people aged 50 years and beyond who seek
treatment at a gender identity clinic service. This is an important
area as older trans people remain invisible in research studies and
often experience double discrimination, being trans as well as
being older. Moreover, they are at a higher risk of developing
adverse effects from CHT42,43 as they are more prone to
comorbidities as well as using CHT without medical advice and
supervision.
The study found that the overwhelming majority of older
people presenting at gender identity clinic services over the age of
50 years old are trans females, with a sex ratio of 23.7:1 over
trans males. To our knowledge, this has not been documented
formally in the empirical literature and is distinctly different from
the sex ratios of trans adolescents and trans adults, which point
toward near parity.18,19,44,45
Whether trans people who transition later in life constitute a
different group compared to their younger counterparts has been
vociferously debated.46,47 Trans people who transition later in
life may have different psychosocial characteristics, but the exact
etiology remains unclear. It remains to be seen how clinically
relevant further classiﬁcation in this context is; ethically there is
general agreement in medicine that like cases should be treated
alike.48 The mainstay physical treatment options remain the
same and include CHT and gender-related surgeries.14,16 There
is a higher risk associated with these treatments for older people,
which should be discussed with patients on an informed consent
model basis.42,43,48,49 Cross-sex hormone use was present in
54% of gender clinic referrals, of whom more than 50% sourced
the hormones via the Internet. It is concerning that 28%of older
trans people who presented at the clinical service had obtained
hormone treatment via the Internet without medical advice. This
is signiﬁcantly higher than previously reported17 and it may be a
reﬂection of the signiﬁcant barriers to treatment for older trans
people. Ageism, discrimination in employment, and lack of social
and family support plus lack of gender identity clinic services,
long waiting lists, and lack of funding8e10 may why older trans
people obtain treatment without medical assistance or sup-
port.9,17 Moreover, it could be argued that overly prescriptive
pathways to access hormone treatment in Standards of Care Q14,16
further increase barriers to treatment.
The ﬁnding that trans females who presented to the clinical
service on CHT were signiﬁcantly younger than their counter-
parts, who were not on CHT may be a reﬂection of the higher
accessibility to the Internet associated with a younger age. Older568
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Table 4. Means (with standard deviations) of the MSPSS, IPP-32, and Experiences of Transphobia Scale for Trans Females Over 50 Years
With and Without Cross-Sex Hormone Treatment (CHT)
Not on treatment Taking cross-sex hormones Total
Mann-Withney UM (SD) M (SD) M (SD)
HADS (n ¼ 68)
Anxiety 7.84 (3.90) 5.03 (3.44) 6.30 (3.89) 341†
Depression 6.68 (4.85) 4.62 (4.03) 5.56 (4.51) 432
RSE (n ¼ 69)
Total 19.59 (6.34) 23.05 (5.32) 21.45 (6.03) 420.5*
MSPSS (n ¼ 68)
Signiﬁcant others 19.57 (8.89) 20.32 (7.69) 19.99 (8.19) 600
Family 15.53 (8.74) 16.24 (6.87) 15.93 (7.70) 553
Friends 16.10 (8.25) 19.87 (5.70) 18.21 (7.14) 464.5
Total 51.20 (21.69) 56.42 (14.09) 54.12 (17.89) 516
IIP-32: Problems
Competition 1.03 (1.13) 0.81 (1.10) 0.92 (1.11) 516
Socialization 0.91 (1.09) 1.46 (1.16) 1.20 (1.15) 375*
Nurturance 0.42 (1.22) 0.59 (0.88) 0.51 (1.05) 532
Independence 0.55 (1.02) 0.42 (0.96) 0.48 (0.98) 586.5
Total 1.31 (0.58) 0.94 (0.59) 1.11 (0.61) 335.5†
Transphobia (n ¼ 70)
Total 1.81 (2.08) 2.05 (1.79) 1.94 (1.91) 528
HADS ¼ Hospital Anxiety and Depression Scale; RSE ¼ Rosenberg Self-Esteem Scale; IIP-32 ¼ Inventory of Interpersonal Problems; MSPSS ¼ Multi-
dimensional Scale of Perceived Social Support.
*P < .05.
†P < .01.
















































































































680people may be less skilled in using computer technology, which
makes obtaining hormones via the Internet more difﬁcult. An
alternative explanation may be that older people are less willing
to initiate hormone treatment that is not prescribed and moni-
tored by a physician. The study also showed that those on CHT
came out and transitioned signiﬁcantly earlier than those trans
females not on treatment. As we do not know how long people
were taking CHT the direction of the association between
starting hormone treatment, coming out as trans, and time of
transition remains unknown. Interestingly, independent of hor-
mone treatment the time between coming out as trans and age of
transition remains around a decade. This is a considerable
amount of time and may well be related to family and work
responsibilities, although future research may want to investigate
the speciﬁc underlying reasons for this.
The life-time prevalence of nonsuicidal self-injury (NSSI; ie,
cutting) was 16.9% in our sample of older trans females, which is
much lower than the prevalence of NSSI in younger trans
females (26.2%),6 but signiﬁcantly higher than the lifetime
prevalence of NSSI in an adult community sample (5.9%).50 As
most injurers report that NSSI functions to alleviate negative
emotions, further research should focus on underlying etiology
and preventative measures.
Older trans females who use cross-sex hormones were found
to be signiﬁcantly less anxious and reported signiﬁcantly higherFLA 5.4.0 DTD  JSXM60_proofself-esteem compared to older trans females who do not use
hormones. The association disappeared for self-esteem when
controlled for problems with socialization. As older trans fe-
males who use cross-sex hormones experienced fewer problems
with socialization than older trans females who did not use
hormones, controlling for this variable known to predict psy-
chopathology was important. This is one of the few studies that
have controlled for predictive variables when studying the role
of treatment in trans people. The study shows that when
controlling interpersonal difﬁculties the levels of anxiety in
trans females on CHT is consistent with other research of
younger trans people who use cross-sex hormones and high-
lights the psychological and social beneﬁts that may be asso-
ciated with CHT for trans people.20e22 However, due to the
cross-sectional nature of this study, cause and effect could not
be concluded. It also must be acknowledged that these trans
females as autonomous agents have sought access to hormone
treatment without assistance or support from gender identity
clinic services. Given the beneﬁts patients may derive from
CHT and bearing in mind the risks associated with CHT that
is not adequately monitored, particularly in older people, a
re-evaluation of the function and purpose of gender identity
clinic services is timely.
A limitation of the study is the cross-sectional nature of the
data. Future research could investigate underlying motives as toJ Sex Med 2016;-:1e9
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Q5
Table 5. Means (with standard deviations) of the HADS and the
Rosenberg Self-esteem Scale Controlled for IPP-32 Socialization
for Trans Females Over the Age of 50 Years With and Without
Cross-Sex Hormone Treatment (CHT)
Not on CHT On CHT Total
FM (SD) M (SD) M (SD)
HADS (n ¼ 68)
Anxiety 7.80 (3.96) 5.14 (3.42) 6.35 (3.88) 5.82*
Depression 6.83 (4.86) 4.75 (4.02) 5.70 (4.51) 1.08
RSE (n ¼ 69)
Total 19.10 (6.34) 22.86 (5.27) 21.18 (6.02) 3.33



















































































































794why people obtain and use CHT without medical advice, what
the associated risks are, if any, and why people transition later in
life. From the current data, it is not possible to determine
whether the psychological beneﬁts associated with the use of
hormone treatment predate or are a consequence of disclosure
of experienced gender and/or social gender role transition. It
also may be that those with better self-esteem, less psychopa-
thology and fewer problems with socialization feel more
conﬁdent to commence treatment without medical advice.
They may use the support and advice of their friends who also
may be taking CHT. Longitudinal data would provide the ideal
avenue to explore this. The study is also limited by selecting a
speciﬁc population of treatment seeking individuals and doing
so in a country in which the waiting list for a ﬁrst appointment
at a gender identity clinic service is long. Hence, the results may
not be generalizable to other older trans females who do not
access clinical services or to other countries with different
healthcare systems. The research makes use of self-reported
questionnaires, and although most are adequately validated
and have been used in trans populations, future research could
use structured clinical interviews to differentiate the clinical
group from those with and without anxiety. A ﬁnal note on the
generalizability of these ﬁndings is that there are particularities
with regards to medical treatment and legislation for trans
person people in the UK. For example, some aspects of
gender reassignment treatment (e.g. CHT and/or genital
reconstructive surgeries) are available through the NHS free at
the point of access, and the Gender Recognition Act 2004
provides legal recognition of a trans individual’s experienced
gender. In addition, the Sex Discrimination (Gender Reas-
signment) Regulations Act 1999, and its amendment in 2008,
deemed it unlawful to discriminate on the basis of gender
reassignment within employment and vocational training, as
well as within the provision of goods, facilities, and services.
Consequently, the experience of living as trans in the United
Kingdom may be different from living as trans in otherJ Sex Med 2016;-:1e9
FLA 5.4.0 DTD  JSXM60_proof  8countries. A cross-cultural validation of the ﬁndings would be
expedient because differences in legislation and health service
provision are likely to affect the experience of being trans.23
CONCLUSION
The majority of older people presenting at gender identity
clinic services over the age of 50 years old are trans females. After
coming out as trans older people take on average about a decade
to fully transition, which may be related to employment or
family responsibilities. More than a quarter of this older trans
population had obtained hormone treatment via the Internet
without medical advice. Older trans females who use cross-sex
hormones were found to be signiﬁcantly less anxious compared
to older trans females who do not use hormones, even when
controlled for interpersonal difﬁculties. Older female trans peo-
ple clearly derive beneﬁts from CHT. Clinicians need to provide
education regarding CHT and advice regular monitoring to
reduce risks associated with CHT.
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